EZI inhibitors, short for enhancer of zeste homolog inhibitors, are a class of chemical compounds that specifically target and inhibit the function of enhancer of zeste homolog proteins, which are a central component of the polycomb repressive complex 2 (PRC2). These proteins, particularly EZH2, play a crucial role in the epigenetic regulation of gene expression through the trimethylation of lysine 27 on histone H3 (H3K27me3), a marker commonly associated with gene silencing. EZI inhibitors are designed to bind to the SET domain of EZH2, thereby preventing the methyltransferase activity of the enzyme. This inhibition leads to a decrease in H3K27me3 levels and consequently affects the epigenetic silencing of genes. By altering the histone methylation landscape, EZI inhibitors can induce changes in the expression patterns of genes that are critical for various cellular processes, including cell differentiation and proliferation.
The development of EZI inhibitors is rooted in the understanding of the molecular mechanisms by which PRC2 regulates gene expression. By binding to the active site of EZH2, these inhibitors can effectively reduce the enzymatic activity responsible for the addition of methyl groups to H3K27. The specificity of EZI inhibitors toward the SET domain is crucial, as it ensures that the off-target effects are minimized, thereby focusing the impact on the PRC2 pathway. The consequent reduction in H3K27me3 levels leads to the reactivation of previously silenced genes, which can result in pronounced changes in cellular behavior. This class of inhibitors is characterized by a range of chemical structures, each with varying degrees of affinity and specificity for the EZH2 SET domain. Researchers are continually synthesizing and evaluating novel compounds within this class to optimize their efficacy and selectivity. The biochemical pathways influenced by EZI inhibitors are complex and involve a network of interactions that extend beyond the immediate action on EZH2, affecting the broader chromatin architecture and gene expression profile of the cell.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. EZI, being a protein that may interact with chromatin, could be indirectly inhibited by the increased acetylation of histones, leading to a conformational change in chromatin structure that disfavors EZI interactions. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat is another histone deacetylase inhibitor. It would enhance histone acetylation, potentially altering gene expression in a way that leads to the downregulation of EZI activity due to chromatin remodeling. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, as a short-chain fatty acid, acts as a histone deacetylase inhibitor. It is likely to cause hyperacetylation of histones, which could disrupt the functional activity of EZI by affecting the transcription of genes that participate in its regulation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is a cyclic peptide that inhibits histone deacetylase, leading to altered chromatin structure and potentially decreasing the functional activity of EZI by modifying the expression of genes critical to its function. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits class I histone deacetylases, leading to changes in gene expression that could result in the downregulation of EZI through epigenetic modulation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent histone deacetylase inhibitor that could decrease EZI functional activity by broadly altering the expression patterns of genes involved in EZI-mediated pathways. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat inhibits histone deacetylase activity, potentially reducing EZI activity by changing the expression of genes that regulate EZI's functional role in the cell. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is a histone deacetylase inhibitor that could lead to the downregulation of EZI by modifying the acetylation status of histones and thereby affecting gene expression profiles. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, commonly known as a mood stabilizer, also functions as a histone deacetylase inhibitor and could indirectly inhibit EZI by altering the transcriptional landscape that regulates EZI's activity. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is a selective inhibitor of class I and class IV histone deacetylases. It could indirectly lower EZI activity by changing gene expression via epigenetic remodeling. | ||||||